Agios and Aurigene signs agreement to develop small molecule inhibitors for cancer metabolism target

Agios Pharmaceuticals and Aurigene Discovery Technologies announced that they have signed a global license agreement to research, develop and commercialize small molecule inhibitors of an undisclosed cancer metabolism target.

According to the agreement, Aurigene will provide Agios exclusive rights to its portfolio of novel small molecules for the undisclosed target. Financial terms of the agreement include a $3 million upfront payment and potential future milestone payments of up to $17 million per licensed product if certain development and regulatory milestones are achieved by Agios. Aurigene is also eligible to receive low single-digit royalties on product sales. Agios will conduct preclinical studies and, if successful, fund further global research and development, as well as regulatory and commercial activities.